Last updated: 26 September 2023 at 4:33pm EST

Shamim Ruff Net Worth




The estimated Net Worth of Shamim Ruff is at least 2 百万$ dollars as of 28 July 2023. Shamim Ruff owns over 8,235 units of Sarepta Therapeutics Inc stock worth over 2,002,114$ and over the last 8 years Shamim sold SRPT stock worth over 0$.

Shamim Ruff SRPT stock SEC Form 4 insiders trading

Shamim has made over 8 trades of the Sarepta Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Shamim exercised 8,235 units of SRPT stock worth 759,267$ on 28 July 2023.

The largest trade Shamim's ever made was exercising 12,138 units of Sarepta Therapeutics Inc stock on 20 July 2017 worth over 168,840$. On average, Shamim trades about 3,075 units every 132 days since 2016. As of 28 July 2023 Shamim still owns at least 15,594 units of Sarepta Therapeutics Inc stock.

You can see the complete history of Shamim Ruff stock trades at the bottom of the page.



What's Shamim Ruff's mailing address?

Shamim's mailing address filed with the SEC is 5320 LEGACY DRIVE, , PLANO, TX, 75024.

Insiders trading at Sarepta Therapeutics Inc

Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over 58,674,663$ worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth 49,516,406$ . The most active insiders traders include John C MartinRichard BarryM Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of 2,737,275$. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth 822,100$.



What does Sarepta Therapeutics Inc do?

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.



Complete history of Shamim Ruff stock trades at Reata Pharmaceuticals Inc、Sarepta Therapeutics Inc

インサイダー
取引
取引
合計金額
Shamim Ruff
ディレクター
オプション行使 759,267$
28 Jul 2023
Shamim Ruff
ディレクター
オプション行使 198,030$
10 Mar 2023
Shamim Ruff
SVP、Chief Regulatory Affairs
オプション行使 59,825$
15 Mar 2018
Shamim Ruff
SVP、Chief Regulatory Affairs
オプション行使 147,600$
6 Nov 2017
Shamim Ruff
SVP、Chief Regulatory Affairs
オプション行使 169,740$
3 Oct 2017
Shamim Ruff
SVP、Chief Regulatory Affairs
オプション行使 168,840$
20 Jul 2017
Shamim Ruff
SVP、Chief Regulatory Affairs
オプション行使 26,240$
8 Nov 2016
Shamim Ruff
SVP、Chief Regulatory Affairs
オプション行使 101,623$
22 Sep 2016


Sarepta Therapeutics Inc executives and stock owners

Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: